Pharmacokinetics of Voxelotor in Patients With Renal and Hepatic Impairment

Two open‐label studies assessed the safety, tolerability, and pharmacokinetics of Oxbryta (voxelotor) in subjects with hepatic or renal impairment. Eight subjects with severe renal impairment (estimated glomerular filtration rate <30 mL/min/1.73 m(2)) and 8 healthy age‐, sex‐, and body mass index...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:J Clin Pharmacol
Prif Awduron: Preston, Richard A., Marbury, Thomas, Balaratnam, Ganesh, Green, Michelle, Dixon, Sandy, Lehrer‐Graiwer, Josh, Washington, Carla
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: John Wiley and Sons Inc. 2020
Pynciau:
Editor's Choice: Special Populations
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC7984382/
https://ncbi.nlm.nih.gov/pubmed/33084052
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jcph.1757
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg